论文部分内容阅读
β—肾上腺素能受体阻滞剂是在1964年首次被应用于治疗高血压。从此以后,在一段时间内许多研究者报告了它可疑的或者仅是部分有效的结果,而使其在抗高血压药物的历史中并不著名。但是,由于证明了心得安的效果与肾素活性的水平有关,故目前在美国重新应用这类药物治疗高血压的兴趣大为增加。用它治疗高血压时副作用少也是推广应用这类药物治疗的另一因素。β—阻滞剂具有选择性作用并且引起不同类型的反应。因此,某化合物可以对心脏受体(心脏的选择性)或者对心外β—受体,如支气管(支气管选择性),血管,或者
Beta-adrenergic receptor blockers were first applied to the treatment of hypertension in 1964. Since then, many researchers report their dubious or only partially valid results over time, making them less well-known in the history of antihypertensive drugs. However, interest in re-applying such drugs in the United States for the treatment of hypertension has so far been greatly increased by the evidence that propranolol is associated with renin activity. Less side effects when it is used to treat hypertension is also another factor to promote the use of such drugs. Beta-blockers have a selective effect and cause different types of reactions. Thus, a compound may act on cardiac receptors (cardiac selectivity) or on extra-cardiac beta receptors such as bronchial (bronchial selectivity), blood vessels, or